Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response

Journal of Virology

Volumn 75, Issue 13, 2001, Pages 6095-6106

  Polyak, S J ^a   Khabar, K S A ^a   Paschal, D M ^a   Ezelle, H J ^a   Duverlie, G ^a   Barber, G N ^a   Levy, D E ^a   Mukaida, N ^a   Gretch, D R ^a  

^a Virology Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUTANT PROTEIN; PROTEIN KINASE; STAT1 PROTEIN; STRUCTURAL PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; GENETIC TRANSCRIPTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REPORTER GENE; TRANSACTIVATION; VIRUS PATHOGENESIS; VIRUS RESISTANCE;

BASE SEQUENCE; DNA-BINDING PROTEINS; DRUG RESISTANCE, MICROBIAL; HELA CELLS; HEPACIVIRUS; HUMANS; INTERFERONS; INTERLEUKIN-8; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0034969251     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.13.6095-6106.2001     Document Type: Article

References (79)

1. Hepatitis C virus, the E2 envelope protein, and the alpha-interferon response
2. Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells
3. Efficient initiation of HCV RNA replication in cell culture
4. Therapy of hepatitis C: Meta-analysis of interferon alpha-2b trials
5. The E3L gene of vaccinia virus encodes and inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase
6. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection
7. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus
8. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
9. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
10. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei
11. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity
12. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A gene
13. Mutations in the nonstructural protein 5A and response to interferon in patients with chronic hepatitis C virus 1b infection
14. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis
15. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes
16. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein
17. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
18. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase
19. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
20. Chemokine receptors and chemokines in HIV infection
21. Regulation of RANTES chemokine gene expression requires cooperativity between NF-κB and IFN-regulatory factor transcription factors
22. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C
23. Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor. SRCAP
24. Tight control of gene expression in mammalian cells by tetracycline responsive promoters
25. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway
26. The interferon sensitivity determining region: All hepatitis C virus isolates are not the same
27. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b
28. Hepatitis C virus NS5A protein is phosphorylated in vitro by a stably bound protein kinase from HeLa cells and by cAMP-dependent protein kinase A-alpha catalytic subunit
29. Characterization of the nuclear localization signal and subcellular distribution of hepatitis C virus nonstructural protein NS5A
30. Genomic structure of the human prototype strain H of hepatitis C virus: Comparison with American and Japanese isolates
31. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator
32. Regulation of the interferon-induced PKR: Can viruses cope?
33. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha
34. Subcellular localization of hepatitis C viral proteins in mammalian cells
35. Analysis of genotypes and amino acid residues 2209-2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy
36. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1
37. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: Specific detection of negative-strand viral RNA in various tissues
38. Effects of adenovirus E1A protein on interferon signaling
39. Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3
40. Pathogenesis, natural history, treatment, and prevention of hepatitis C
41. Essential role of interferon regulatory factor 3 in direct activation of RANTES chemokine transcription
42. Therapy of hepatitis C: Overview
43. Cytokines in alcoholic liver disease
44. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
45. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon
46. Detection of hepatitis C virus RNA in peripheral blood mononuclear cells of infected patients by in situ hybridization
47. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins
48. Properties of pro-inflammatory cell type-specific leukocyte chemotactic cytokines, interleukin 8 (IL-8) and monocyte chemotactic and activating factor (MCAF)
49. Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line, THP-1, through acting concurrently on AP-1- and NF-κB-binding sites of the interleukin-8 gene
50. Chemokine receptors: Structure, function and role in microbial pathogenesis
51. Prospective characterization of full-length HCV NS5A quasispecies during induction and combination antiviral therapy
52. Downregulation of interleukin 8 gene expression in human fibroblasts: Unique mechanism of transcriptional inhibition by interferon
53. Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-κB factors
54. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response
55. Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations
56. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon
57. Characterization of the effects of hepatitis C virus non-structural 5A protein expression in human cell lines and on interferon-sensitive virus replication
58. Molecular basis for responsiveness to anti-viral therapy in hepatitis C
59. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection
60. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
61. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
62. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: Properties of the NS5A-associated kinase
63. A suggested extension of the HCVISDR does not alter our former conclusions on its predictive value for IFN response
64. The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element
65. Activation of transcription factors NF-κB and NF-IL-6 by human immunodeficiency virus type 1 protein R (Vpr) induces interleukin-8 expression
66. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus
67. Cleavage of hepatitis C virus nonstructural protein 5A by a caspase-like protease(s) in mammalian cells
68. Hepatitis C and alcohol
69. Interferon-alpha and interferon-gamma down-regulate the production of interleukin-8 and ENA-78 in human monocytes
70. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon
71. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alpha
72. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection
73. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling
74. The amino terminal deletion mutants of hepatitis C virus nonstructural protein NS5A function as transcriptional activators in yeast
75. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A
76. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
77. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation
78. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alpha